Medicine
fromwww.scientificamerican.com
4 hours agoExperimental GLP-3 weight loss drug retatrutide shows promising results in clinical trial
Retatrutide, a triple-receptor GLP-3 agonist drug, achieved up to 36.6 pounds of average weight loss and improved blood sugar control in phase 3 clinical trials for type 2 diabetes.